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Background. Identifying determinants of morbidity and mortality may help target future interventions for human immunode-
ﬁciency virus (HIV)–infected children.
Methods. CD4+ T-cell count, HIV viral load, and levels of biomarkers (C-reactive protein, tumor necrosis factor α [TNF-α],
interleukin 6 [IL-6], and soluble CD14) and interleukin 7 were measured at antiretroviral therapy (ART) initiation in the
ARROW trial (case-cohort design). Cases were individuals who died, had new or recurrent World Health Organization clinical
stage 4 events, or had poor immunological response to ART.
Results. There were 115 cases (54 died, 45 had World Health Organization clinical stage 4 events, and 49 had poor immuno-
logical response) and 485 controls. Before ART initiation, the median ages of cases and controls were 8.2 years (interquartile range
[IQR], 4.4–11.4 years) and 5.8 years (IQR, 2.3–9.3 years), respectively, and the median percentages of lymphocytes expressing CD4
were 4% (IQR, 1%–9%) and 13% (IQR, 8%–18%), respectively. In multivariable logistic regression, cases had lower age-associated
CD4+ T-cell count ratio (calculated as the ratio of the subject’s CD4+ T-cell count to the count expected in healthy individuals of the
same age; P < .0001) and higher IL-6 level (P = .002) than controls. Clustering biomarkers and age-associated CD4+ and CD8+ T-cell
count ratios identiﬁed 4 groups of children. Group 1 had the highest frequency of cases (41% cases; 16% died) and profound
immunosuppression; group 2 had similar mortality (23% cases; 15% died), but children were younger, with less profound immu-
nosuppression and high levels of inﬂammatory biomarkers and malnutrition; group 3 comprised young children with moderate
immunosuppression, high TNF-α levels, and high age-associated CD8+ T-cell count ratios but lower frequencies of events (12%
cases; 7% died); and group 4 comprised older children with low inﬂammatory biomarker levels, lower HIV viral loads, and good
clinical outcomes (11% cases; 5% died).
Conclusions. While immunosuppression is the major determinant of poor outcomes during ART, baseline inﬂammation is an
additional important factor, identifying a subgroup of young children with similar mortality. Antiinﬂammatory interventions may
help improve outcomes.
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Approximately 760 000 children are currently receiving antire-
troviral therapy (ART), leading to a 40% reduction in human
immunodeﬁciency virus (HIV) infection–related mortality
since 2005 [1], despite pediatric ART coverage remaining at
only 30% in 2012 [2]. Over 90% of HIV-infected children
live in sub-Saharan Africa, where advanced disease and
undernutrition contribute to high mortality (3%–19%) in
the ﬁrst year of ART [3–8].
HIV infection is characterized by immune activation in
adults, in whom baseline markers of inﬂammation and coagu-
lation predict mortality independently of CD4+ T-cell count
and HIV viral load [9–17].Much less is known about the causes
and consequences of inﬂammation in HIV-infected children
[18], and no studies to date have explored associations between
baseline levels of inﬂammatory biomarkers and mortality in
children starting ART. Identifying factors associated with mor-
bidity, mortality, and poor immunological response at ART ini-
tiation is important, to target future interventions in children
who will need to receive lifelong treatment. We therefore char-
acterized immunodeﬁciency and inﬂammation in a large cohort
of children aged 3 months to 17 years who were starting ART in
Uganda and Zimbabwe, to determine the impact of these fac-
tors on morbidity, mortality, and immune reconstitution.
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METHODS
In the ARROW trial (ISRCTN24791884), previously untreated
Ugandan/Zimbabwean children aged 3 months to 17 years
who were eligible for ART on the basis of 2006 World Health
Organization (WHO) criteria were randomized 1:1 to undergo
clinically driven monitoring versus laboratory plus clinical
monitoring for toxicity (via hematological and biochemical
analyses) and efﬁcacy (via CD4+ T-cell data) [19]. Children
were also randomized 1:1:1 in a factorial design to receive
lamivudine, abacavir, and nonnucleoside reverse transcrip-
tase inhibitor (NNRTI) continuously (arm A) or induction-
maintenance therapy with lamivudine, abacavir, NNRTI,
and zidovudine for 36 weeks, followed by lamivudine, abaca-
vir, and NNRTI (arm B) or lamivudine, abacavir, and zidovu-
dine (arm C), as previously described [19]. The NNRTI
(nevirapine/efavirenz) was chosen by clinicians. Caregivers
gave written consent; older children (age, 8–17 years) aware
of their HIV status also gave assent or consent, as per local
guidelines. The trial and immunology substudy were ap-
proved by Research Ethics Committees in Uganda, Zimba-
bwe, and the United Kingdom.
Study Subjects and Measurements
This study used a case-cohort design. Cases were individuals
who died, who had new or recurrent WHO clinical stage 4
events during follow-up (to trial closure; median follow-up
duration, 4 years), or poor immunological response to ART
(percentage of lymphocytes expressing CD4, ≤ 15% through 3
years of ﬁrst-line ART, allowing a single measurement of
>15%). Controls comprised 316 children in a longitudinal
immunology substudy (the last 6 months of recruitment
[May–November 2008]) and a random 23% sample of all
remaining nonsubstudy children, to reach a sample size of
600 children (Supplementary Figure 1).
In cryopreserved plasma samples obtained before ART initi-
ation (ie, at enrollment) or trial screening (maximum, 30 days
before enrollment), baseline levels of inﬂammatory biomarkers
(C-reactive protein [CRP], tumor necrosis factor α [TNF-α], in-
terleukin 6 [IL-6], and soluble CD14 [sCD14]) and interleukin
7 (IL-7) were measured by an enzyme-linked immunosorbent
assay (R&D Systems, Oxford, United Kingdom), and viral
load was measured by the Abbott m2000sp/rt (Uganda) or
Roche COBAS Amplicor Monitor v1.5 (Zimbabwe) system.
Total CD4+ and CD8+ T cells were measured in real time. In
Uganda, children in the immunology substudy underwent
whole-blood immunophenotyping, using anti-CD4-PerCP (Bec-
ton Dickinson [BD]), anti-CD45RA-APC (Caltag Medsytems),
anti-CD31-PE (eBioscience), and either anti-Ki67-FITC (BD;
after nuclear membrane permeabilization) or anti-HLA-DR-
FITC (BD), with data acquired on a BD FACSCalibur ﬂow
cytometer. Analysis was undertaken using Cellquest (BD).
In the immunology substudy, viral loads were assayed at weeks
4, 24, 36, and 48 after ART initiation and every 24 weeks there-
after. Viral load response was deﬁned as an HIV viral load of
<10 000 copies/mL or a >1 log10 decrease in viral load at week
4, a viral load of <5000 copies/mL at week 24, and, subsequently,
viral loads of <80 copies/mL at all measurements through 3 years
(the lower limit of 80 copies/mL was selected because many
samples had to be diluted owing to small volumes), allowing
>80 copies/mL at week 36 only, provided that the viral load
was exhibiting a decreasing trend (as observed among slow re-
sponders). Children were classiﬁed as having blips if the viral
load returned to <80 copies/mL. Those in whom the viral did
not return to <80 copies/mL but remained <5000 copies/mL
were deﬁned as having persistent low-level viral load, whereas
individuals with a conﬁrmed viral load of ≥5000 copies/mL
after week 24 were deﬁned as rebounders.
Analysis
Analysis considered all inﬂammatory biomarkers, IL-7, age-
associated CD4+ and CD8+ T-cell counts (hereafter termed
“CD4 for age” and “CD8 for age,” respectively, and calculated
as the ratio of the subject’s CD4+ or CD8+ T-cell count to the
count expected in healthy individuals of the same age; a maxi-
mum Spearman rho of 0.57 between any pair of parameters in-
dicated a low risk of collinearity), and the following CD4+ T-cell
subpopulations as a percentage of the total CD4+ T-cell popu-
lation: CD45RA+ (naive), CD45RA+CD31+ (recent thymic em-
igrants), HLA-DR+ (activated), and Ki67+ (proliferating). These
measurements were log2 transformed for normality; viral load
was log10 transformed. Height for age and body mass index
(BMI) for age were calculated using WHO reference values
[20]; because weight for age does not cover the full age range,
this was calculated using United Kingdom reference data [21].
To reduce the potential inﬂuence of outliers, measurements
were truncated at the 2.5th and 97.5th percentiles (that is, values
above the 97.5th percentile were set to the 97.5th percentile, and
values below the 2.5th percentile were set to the 2.5th
percentile).
As analyses included all substudy children and a sample of
the remaining children, we prespeciﬁed an unmatched case-
control design, using univariable rank sum and χ2 tests and
multivariable logistic regression, forcing immunology substudy
into the models as a stratiﬁer. Sensitivity analyses used the Pren-
tice method with time-to-event data for a case-cohort design
[22], considering children from the immunology substudy as
1 subcohort and sampling 23% of cases who were not from
the immunology substudy as a second subcohort. Variable
selection was based on backward elimination with an exit
P value of .05, including nonlinearity, based on fractional
polynomial modeling, when P < .01 (Stata mfp). Interactions
between variables in the ﬁnal model were investigated and
included when Pheterogeneity < .01.
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To identify groups of children based on pre-ART laboratory
parameters (CRP, TNF-α, IL-6, sCD14, and IL-7 levels; CD4 for
age; CD8 for age; and viral load), we used principal components
analysis (correlation matrix) followed by hierarchical clustering
using complete linkage (with the number of clusters identiﬁed
using the Calinski/Harabasz stopping rule). The independent
interrelationships between laboratory parameters, age at ART
initiation, pre-ART weight for age, pre-ART height for age,
pre-ART BMI for age, and sex were identiﬁed using backward
elimination (exit P value, .01; inclusion of nonlinearity when
P < .001) from multivariable linear regression models for each
laboratory factor in turn as the outcome and all other factors
as explanatory variables. In children with immunophenotyping
data, additional relationships between each factor and CD4+ T-
cell subpopulations were identiﬁed (the proportion of recent
thymic emigrant CD4+ T cells was not considered as it was
strongly associated with the proportion of naive CD4+ T cells;
Spearman correlation, 0.89); (exit P value, .05; inclusion of non-
linearity when P < .01, owing to smaller numbers).
All analyses were performed using Stata 14.1 (StataCorp). All
P values are 2 sided.
RESULTS
A total of 600 of the 1206 ARROW children were included
by design; 115 were cases (54 died, 45 had new/recurrent
WHO clinical stage 4 events, and 49 had poor immunological
response; some children met multiple deﬁnitions), and 485 were
controls. Among cases, deaths and WHO clinical stage 4 events
occurred at a median of 19 weeks (range, 1–232 weeks) and 63
weeks (range, 1–212 weeks), respectively, after starting ART;
in immunological non-response, the median CD4+ T-cell per-
centage over the ﬁrst 3 years of ART was 7% (IQR, 3%–11%).
Pre-ART biomarker data were available for 113 cases (98%) and
466 controls (96%); 1 control had a missing pre-ART viral load,
leaving 578 children in the analyses. Immunophenotyping data
were available for 170 controls (37%) and 9 cases (8%; Uganda
only). In 299 children in the immunology substudy who had
pre-ART biomarker and longitudinal viral load measurements,
virological response was deﬁned in 292 (98%) who were
followed up at 24 weeks.
Characteristics at ART Initiation
Cases were signiﬁcantly older than controls (median age, 8.2
years [IQR, 4.4–11.4 years] vs 5.8 years [IQR, 2.3–9.3 years])
and had a lower pre-ART CD4+ T-cell percentage (4% [IQR,
1%–9%] vs 13% [IQR, 8%–18%]), a lower CD4 for age (median,
0.08 vs 0.29), and a lower ratio of CD4+ to CD8+ T cells (median,
0.1 vs 0.3; P < .0001 for all comparisons; Table 1). The ratio of
CD4+ to CD8+ T cells was highly correlated with the CD4 for
age (Spearman rho, 0.89; P < .0001). CRP, IL-6, and sCD14 levels
were all signiﬁcantly higher and the TNF-α level signiﬁcantly
lower in cases, compared with controls (P < .01). In multivariable
logistic regression analysis considering all factors from Table 1,
cases independently had a lower pre-ART CD4 for age (adjusted
odds ratio [aOR], 0.56 per 2-fold increase [95% conﬁdence inter-
val {CI}, .49–.64]; P < .0001) and a higher pre-ART IL-6 level
(aOR, 1.54 per 2-fold increase [95% CI, 1.18–2.01]; P = .002).
There were no independent additional effects of pre-ART base-
line CRP, sCD14, or TNF-α concentrations (P > .15), although a
model containing CRP level instead of IL-6 level was similarly
predictive (Akaike information criterion [AIC], 405 vs 404 in
the original model), and a model containing CD4+ T-cell per-
centage instead of CD4 for age was only slightly less predictive
(AIC, 412). There was a marginal trend toward cases indepen-
dently having a higher pre-ART viral load (P = .08), a lower
weight for age or BMI for age (P = .0503 or P = .08, respectively),
and a lower CD4+ T-cell percentage (P = .06) than controls (other
model coefﬁcients were unchanged). Despite strong univari-
able effects, there was no independent effect of age (P = .23),
ratio of CD4+ to CD8+ T cells (P = .22), WHO clinical stage
(P = .48), or any other baseline factor (P > .1). Sensitivity anal-
yses using Prentice time-to-event methods supported CD4 for
age and IL-6 level as the most prognostic biomarkers (Supple-
mentary Table 1).
At ART Initiation, Children Fall Into Subgroups With Different ART
Responses
Whereas multivariable regression identiﬁes the key determi-
nants of poor outcomes, it does not inform how these risk fac-
tors are distributed across individuals. We therefore used
principal components analysis to identify the most informative
combinations of biomarkers, viral load, CD4 for age, and CD8
for age (Supplementary Table 2). Hierarchical clustering identi-
ﬁed 4 groups of children at ART initiation, strongly associated
with case versus control status (P < .001, by χ2 analysis;
P < .0001, by logistic regression with adjustment for immunol-
ogy substudy; Table 2 and Figure 1A).
Ordering by decreasing proportion of cases, group 1 (n = 135;
41% cases) was characterized by profound immunosuppression
(median CD4+ T-cell percentage, 3.0%; P < .0001 vs other
groups); group 2 (n = 48; 23% cases) was less immunosup-
pressed, and group 3 (n = 264; 12% cases) and group 4 (n = 131;
11% cases) were least immunosuppressed (P < .01 vs group 2). De-
spite their profound immunosuppression, the viral load in group 1
was similar to that in group 3 (P = .14) and only marginally lower
than in group 2 (P = .07). Viral load was lower in group 4 than in
all other groups (P < .0001). Median levels of the inﬂammatory
markers CRP and IL-6 were highest in group 2 (35.3 mg/L and
26.4 pg/mL, respectively) and lowest in group 4 (P < .0001 for
both markers vs all other groups). sCD14 level was signiﬁcantly
lower in group 3 than in both groups 1 and 2 (P < .0001) and
lower in group 4 than in all other groups (P < .0001). TNF-α
level and CD8 for age were signiﬁcantly higher in groups 2 and
3 than in groups 4 and 1 (P < .05).
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Considering factors not used to deﬁne subgroups, weight for
age was highest in group 4 (P < .0001) and lowest in group 2
(P < .05; Figure 2). Height for age similarly was highest in
group 4 (P < .0001) and lowest in groups 2 and 3 (P < .01).
BMI for age generally increased across all groups. Whereas chil-
dren in group 1 (median age, 7.9 years) were older than those in
Table 1. Characteristics at Antiretroviral Therapy (ART) Initiation and Impact on ART Response
Factor at ART Initiation Overall (n = 578) Cases (n = 113) Controls (n = 465)
Univariable P,
Cases vs Controlsa
Multivariable OR (95%
CI); P Value
Country/center .89
Uganda/Entebbe (nonurban) 81 (14.0) 18 (15.9) 63 (13.5) . . .
Uganda/JCRC (urban) 146 (25.3) 28 (24.8) 118 (25.4) . . .
Uganda/PIDC (urban) 150 (26.0) 27 (23.9) 123 (26.5) . . .
Zimbabwe/Harare (urban) 201 (34.8) 40 (35.4) 161 (34.6) . . .
In immunology substudy 299 (51.7) 16 (14.2) 283 (60.9) <.0001 0.08 (.04–.15); <.0001
Male sex 287 (49.7) 62 (54.9) 225 (48.4) .22 . . .
Age, y 6.3 (2.4, 9.7) 8.2 (4.4, 11.4) 5.8 (2.3, 9.3) <.0001 . . .
Weight for ageb −2.3 (−3.4 to −1.4) −2.7 (−4.2, −1.7) −2.2 (−3.2, −1.3) .0008 . . .
Height for agec −2.5 (−3.4 to −1.6) −2.4 (−3.5, −1.5) −2.5 (−3.5, −1.6) .89 . . .
BMI for agec −0.7 (−1.6, 0.2) −1.3 (−2.3, −0.5) −0.6 (−1.5, 0.2) <.0001 . . .
Viral load, copies/mL 225 600 (73 800–624 200) 275 100 (143 700, 663 800) 212 700 (62 900, 613 800) .03 . . .
CD8+ T-cell percentage 51.0 (41.0, 60.0) 54.0 (46.0, 65.0) 50.0 (40.0, 60.0) .0008 . . .
CD8 for age 1.9 (1.3, 2.8) 1.6 (1.0, 2.3) 2.0 (1.3, 2.8) .0007 . . .
CRP level, mg/L 4.5 (1.4, 15.6) 7.8 (1.9, 23.3) 4.0 (1.3, 13.8) .008 . . .
sCD14 level, mg/L 2.1 (1.7, 2.6) 2.4 (1.8, 2.9) 2.1 (1.7, 2.5) .0007 . . .
IL-6 level, pg/mL 6.1 (4.7, 9.5) 8.1 (5.6, 11.6) 5.8 (4.6, 8.7) <.0001 1.54 per 2-fold increase
(1.18–2.01) ; .002
TNF-α level, pg/mL 22.6 (19.0, 28.0) 20.2 (17.5, 24.1) 23.3 (19.6, 28.6) <.0001 . . .
IL-7 level, pg/mL 9.3 (3.8, 16.8) 8.8 (5.4, 17.6) 9.5 (3.5, 16.7) .28 . . .
CD4+ T-cell percentage 12.0 (6.0, 17.0) 4.0 (1.0, 9.0) 13.0 (8.0, 18.0) <.0001 . . .
CD4 for age 0.25 (0.11, 0.41) 0.08 (0.02, 0.19) 0.29 (0.17, 0.44) <.0001 0.56 per 2-fold increase
(.49–.64); <.0001
Ratio of CD4+ to CD8+ T cells 0.2 (0.1, 0.4) 0.1 (0.0, 0.2) 0.3 (0.2, 0.4) <.0001 . . .
Hemoglobin level, g/dL 10.5 (9.5, 11.5) 10.5 (9.5, 11.4) 10.5 (9.5, 11.6) .77 . . .
WHO clinical stage .048
1 or 2 172 (29.8) 25 (22.1) 147 (31.6) . . .
3 or 4 406 (70.2) 88 (77.9) 318 (68.4) . . .
CD4+ T-cell monitoring .73
Yes 295 (51.0) 56 (49.6) 239 (51.4) . . .
No 283 (49.0) 57 (50.4) 226 (48.6) . . .
ART strategy .52
Arm A (3TC, ABC, NNRTI
throughout)
202 (34.9) 44 (38.9) 158 (34.0) . . .
Arm B (ZDV for 36 wk) 190 (32.9) 37 (32.7) 153 (32.9) . . .
Arm C (long-term ZDV, 3
NRTIs after wk 36)
186 (32.2) 32 (28.3) 154 (33.1) . . .
Initial NNRTI .46
Nevirapine 356 (61.6) 73 (64.6) 283 (60.9) . . .
Efavirenz 222 (38.4) 40 (35.4) 182 (39.1) . . .
Primary caregiver .0005
Mother 317 (54.9) 45 (40.2) 272 (58.5) . . .
Other 260 (45.1) 67 (59.8) 193 (41.5) . . .
Missingd 1 1 0 . . .
Data are median values (interquartile ranges) or no. (%) of subjects. There was no evidence of interactions in the multivariable model (P > .1). See Supplementary Table 1 for sensitivity analysis
using time to event rather than binary outcomes and the Prentice method to adjust for the case-control design.
Abbreviations: 3TC, lamivudine; ABC, abacavir; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; IL-6, interleukin 6; IL-7, interleukin 7; NNRTI, nonnucleoside reverse
transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio; sCD14, soluble CD14; TNF-α, tumor necrosis factor α; WHO, World Health Organization; ZDV, zidovudine.
a By rank sum or χ2 tests of observed data.
b Because WHO reference values for weight for age only cover children <121 months, this variable was calculated using United Kingdom reference values, which cover the full age range of
ARROW children (Spearman correlation between United Kingdom and WHO reference values, 0.99 for 451 children age <121 months).
c Calculated using WHO reference values.
d The mode was assumed in multivariate analyses.
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Table 2. Subgroups of Children at Antiretroviral Therapy (ART) Initiation Identified From Clustering and Impact on ART Response
Variable Group 1 (n = 135) Group 2 (n = 48) Group 3 (n = 264) Group 4 (n = 131) P Valuee
Factors contributing to clustering
CD4 for age 0.03 (0.01, 0.12)a,b,c 0.22 (0.12, 0.33)b,c,d 0.32 (0.22, 0.48)a,d 0.30 (0.21, 0.45)a,d <.0001
Viral load, copies/mL 275 100 (145 100, 748 700)c 626 600 (144 900, 1254 900)b,c 272 000 (72 600, 673 700)a,c 107 200 (30 600, 285 300)a,b,d <.0001
sCD14 level, mg/L 2.5 (2.0, 2.9)b,c 2.6 (2.2, 3.2)b,c 2.2 (1.6, 2.6)a,c,d 1.8 (1.4, 2.1)a,b,d <.0001
CRP level, mg/L 6.4 (5.2, 9.2)a,c 35.3 (17.4, 76.3)b,c,d 4.5 (1.8, 12.1)a,c 1.2 (0.7, 2.8)a,b,d <.0001
IL-6 level, pg/mL 6.4 (5.2, 9.2)a,c 26.4 (16.7, 40.0)b,c,d 6.7 (5.3, 9.4)a,c 4.2 (3.7, 5.0)a,b,d <.0001
TNF-α level, pg/mL 19.8 (17.2, 23.5)a,b 27.8 (20.6, 33.0)c,d 25.8 (22.1, 31.7)c,d 19.1 (17.2, 21.9)a,b <.0001
CD8 for age 1.2 (0.8, 1.6)a,b,c 2.2 (1.5, 2.7)b,c,d 2.4 (1.8, 3.6)a,c,d 1.7 (1.3, 2.4)a,b,d <.0001
IL-7 level, pg/mL 11.0 (6.6, 19.0)a,c 6.4 (2.0, 16.9)b,c,d 11.3 (6.1, 18.1)a,c 2.9 (1.4, 7.0)a,b,d <.0001
Baseline factors not contributing to clustering
Age, y 7.9 (5.2, 11.0) 4.1 (1.7, 8.1) 3.6 (1.9, 8.1) 8.4 (5.1, 11.5) <.0001
CD4+ T-cell percentage 3.0 (1.0, 8.0) 12.0 (5.5, 14.0) 13.0 (9.0, 18.0) 15.0 (11.0, 22.0) <.0001
Hemoglobin level, g/dL 10.6 (9.4, 11.5) 9.6 (9.1, 10.6) 10.3 (9.3, 11.1) 11.6 (10.5, 12.1) <.0001
Neutrophil count, ×109 cells/L 1.8 (1.2, 2.6) 2.4 (1.5, 3.6) 2.3 (1.6, 3.1) 1.8 (1.5, 2.5) <.0001
WHO clinical stage .11
1 or 2 44 (32.6) 12 (25.0) 68 (25.8) 48 (36.6)
3 or 4 91 (67.4) 36 (75.0) 196 (74.2) 83 (63.4)
Current WHO clinical stage 3 or 4 illness at baselinef 42 (31.1) 21 (43.8) 111 (42.0) 19 (14.5) <.0001
Tuberculosis at baseline 9 (6.7) 3 (6.3) 24 (9.1) 4 (3.1) .17
Receiving antibiotic treatment at baseline (excluding tuberculosis treatment) 20 (14.8) 15 (31.3) 33 (12.5) 17 (13.0) .008
Outcome
Case 55 (40.7) 11 (22.9) 32 (12.1) 15 (11.5) <.0001
Died 21 (15.6) 7 (14.6) 18 (6.8) 7 (5.3) .03
Weeks from randomization to death 19.6 (12.4, 85.9) 5.1 (2.3, 15.3) 16.5 (6.7, 32.9) 136.9 (36.3, 172.0)
WHO clinical stage 4 event 25 (18.5) 4 (8.3) 11 (4.2) 3 (2.3) <.0001
Weeks from randomization to first WHO clinical stage 4 event 53.0 (6.4, 109.1) 104.1 (47.2, 117.6) 43.0 (26.0, 144.1) 156.4 (4.0, 161.9)
Poor immunological response 31 (23.0) 0 (0.0) 8 (3.0) 10 (7.6) <.0001
WHO clinical stage 3 or 4 or death 44 (32.6) 16 (33.3) 35 (13.3) 15 (11.5) <.0001
Malnutrition as WHO clinical stage 3 or 4 or cause of death 10 (7.4) 4 (8.3) 8 (3.0) 2 (1.5) .03
Tuberculosis 11 (8.1) 7 (14.6) 10 (3.8) 7 (5.3) .02
Hospitalized 70 (51.9) 24 (50.0) 109 (41.3) 29 (22.1) <.0001
Viral load responseg .20
Responded 20 (36.4) 5 (23.8) 36 (24.8) 29 (40.8)
Had blip 21 (38.2) 8 (38.1) 73 (50.3) 24 (33.8)
Had persistent low-level viral load 4 (7.3) 1 (4.8) 13 (9.0) 6 (8.5)
Had rebound or no response 10 (18.2) 7 (33.3) 23 (15.9) 12 (16.9)
Data are median values (interquartile ranges) or no. (%) of subjects.
Abbreviations: CRP, C-reactive protein; IL-6, interleukin 6; IL-7, interleukin 7; sCD14, soluble CD14; TNF-α, tumor necrosis factor α; WHO, World Health Organization.
a P≤ .05, by the rank sum test, compared with group 2.
b P≤ .05, by the rank sum test, compared with group 3.
c P≤ .05, by the rank sum test, compared with group 4.
d P≤ .05, by the rank sum test, compared with group 1.
e Based on logistic regression analysis, accounting for immunology substudy as a stratifier for the case-control outcome; χ2 or rank sum tests were used otherwise.
f See Supplementary Table 3 for details.
g Defined only among 292 of 299 children in the immunology substudy who were alive and followed up at 24 weeks (5 died at ≤24 weeks; 2 died at 25–29 weeks without a viral load measurement after week 24). See “Methods” section for definitions. Only 2
children (one each in groups 3 and 4) were nonresponders, defined as never having a viral load of <5000 copies/mL.
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groups 2 and 3 (P < .0001), counterintuitively so were children
in group 4 (median age, 8.4 years; P < .0001 vs groups 2 and 3).
As expected, group 1 had the lowest proportion of naive
(CD45RA+) and recent thymic emigrant (CD45RA+CD31+)
CD4+ T cells (P < .01 vs other groups) and the highest propor-
tion of activated (HLA-DR+) and proliferating (Ki67+) CD4+ T
cells (P < .05). However, recent thymic emigrant proportions
were also lower in group 3, compared with group 4 (P = .04),
and the proportion of Ki67+ CD4+ T cells was higher in
group 3 than in groups 2 and 4 (P < .05); there were no other
signiﬁcant differences in CD4+ T-cell subpopulations or activa-
tion markers among groups 2–4 (P > .05). Interestingly, group 2
also had lower pre-ART hemoglobin level, and group 2 (43.8%)
and group 3 (42.0%) had more children with current WHO
clinical stage 3 or 4 illnesses at baseline, compared with group
1 (31.1%) and group 4 (14.5%; P < .0001; Table 2 and Supple-
mentary Table 3). Percentages of children with tuberculosis
were similar in group 1 (6.7%; 9 subjects) and group 2 (6.3%;
2 subjects) at baseline; the greatest excess was in unexplained
severe wasting/malnutrition (4 subjects [3.0%] in group 1 versus
10 [20.8%] in group 2). However, weight for age was only mod-
estly negatively correlated with IL-6 level (Spearman rho, −0.28;
P < .0001) and CRP level (Spearman rho, −0.15; P = .0002).
Taken together, group 1 comprised older children with pro-
found immunosuppression, low proportions of naive and recent
thymic emigrant CD4+ T cells, and high proportions of activat-
ed and proliferating CD4+ T cells; group 2 comprised younger
children with less profound immunosuppression but high levels
of inﬂammation and malnutrition; group 3 similarly comprised
younger children with moderate immunosuppression, high
TNF-α levels, and CD8 for age; whereas group 4 comprised
older children with moderate immunosuppression, low viral
loads, and low levels of inﬂammation. Groups 1 and 2 had sim-
ilar overall mortality (16% and 15%, respectively), with deaths
occurring shortly after ART initiation in both groups (median,
20 and 5 weeks), despite their signiﬁcant differences in pre-ART
CD4+ T-cell counts. The excess of cases in group 1 was predom-
inantly due to immunological nonresponse (Figure 1B). The
proportions with WHO clinical stage 3 or 4 events/death or
hospitalization during ART generally decreased across groups
1–4, similar to the overall case proportion, although tuberculo-
sis was more common in group 2 (14.6%) than in group 1
(8.1%; Supplementary Figure 2).
Virological responses following ART initiation were similar
between groups; in particular, viral load suppression was not
signiﬁcantly poorer in group 1 (children with profound immu-
nosuppression) than in other groups (P = .32, by the χ2 test).
The main difference in virological response was a greater pro-
portion of children with virological blips in group 3 (younger
children with moderate immunosuppression but high TNF-α
levels and CD8 for age, 50% of whom had had blips), compared
with other groups (P = .02). There was also a trend toward more
rebound/nonresponse in group 2 (high inﬂammatory markers;
33% with rebound or no response), compared with other groups
(P = .054).
Interrelationships Between Biomarker Levels, Viral Load, and Age at
ART Initiation
Finally, we explicitly investigated the independent relationships
between laboratory parameters and age at ART initiation in a
cross-sectional analysis, considering each parameter in turn as
the dependent variable (Supplementary Figure 3). CD4 for age
was independently positively associated with CD8 for age and
TNF-α level and negatively associated with IL-7 level, sCD14
level, viral load, and age at ART initiation; however, there was
no independent association between IL-6 or CRP level and CD4
for age after adjustment for these other factors. IL-6 level was
positively associated with viral load, CRP level, TNF-α level,
and sCD14 level. Pre-ART CRP level was positively associated
with only sCD14 and IL-6 levels, and sCD14 level was positively
associated with only IL-6 and CRP levels and negatively
Figure 1. Subgroups of children at antiretroviral therapy (ART) initiation, identified from clustering of principal components. A, Compared to first 2 principal components. B,
Compared to case vs control status. Abbreviation: WHO-4, World Health Organization clinical stage 4.
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Figure 2. Characteristics in subgroups of children before antiretroviral therapy initiation. P < .0001 for all comparisons except the percentage of CD4+HLA-DR+ T cells (P = .03,
by the rank sum test). CD4+ T-cell subpopulations (CD45RA+, CD45RA+CD31+, HLA-DR+, and Ki67+) measured in only 37, 13, 81, and 53 children in groups 1, 2, 3, and 4,
respectively. The top 8 plots are factors used to define subgroups (through clustering of principal components). Abbreviations: BMI, body mass index; CRP, C-reactive protein;
IL-6, interleukin 6; IL-7, interleukin 7; sCD14, soluble CD14; TNF-α, tumor necrosis factor α.
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associated with CD4 for age. Viral load was positively associated
with TNF-α and IL-6 levels and negatively associated with CD4
for age and age. IL-7 level was negatively associated with CD4
for age and positively associated with TNF-α level but not with
any other biomarkers. The only inﬂammatory biomarker inde-
pendently associated with any cell subpopulation was TNF-α
(positively with percentage of Ki67+ CD4+ T cells), although,
as expected, the percentage of CD45RA+ CD4+ T cells was pos-
itively associated with CD4 for age, and the percentage of Ki67+
CD4+ T cells was negatively independently associated with CD4
for age.
DISCUSSION
ART has transformed outcomes for HIV-infected children in
sub-Saharan Africa [1]. However, pediatric treatment coverage
is currently only 30%; therefore, large numbers of HIV-infected
children will start ART over the next decade [2]. Historically,
many children were older with advanced disease at ART initia-
tion [23]; recent WHO guidelines recommend treatment for all
HIV-infected children [24], so those starting ART might be
expected to be younger, with less severe immunosuppression.
However, this large cohort of African children shows that inﬂam-
mation is a major pre-ART determinant of morbidity and mor-
tality, independently of immunosuppression. Furthermore, a
distinct group of younger children with high inﬂammation
were at particularly high risk of early mortality during ART, de-
spite only moderate immunosuppression, highlighting the need
to target underlying pathogenic processes to improve outcomes
in high-risk children, despite universal availability of ART.
Immunosuppression and immune activation are the hall-
marks of HIV infection [25]. In the setting of chronic in-
ﬂammation, there is increased CD4+ T-cell turnover and an
impaired regenerative response to homeostatic signals [26,
27]. CD4+ T-cell depletion and inﬂammation are therefore
highly interlinked processes [28] that drive disease progression
in HIV-infected adults [9–11, 13, 15–17]. To our knowledge,
ours is the ﬁrst study to evaluate the associations between im-
munodeﬁciency, inﬂammatory biomarkers, and mortality in
HIV-infected children, and it conﬁrms that there are similarly
2 pathways (immunosuppression and inﬂammation) underly-
ing serious clinical outcomes in pediatric HIV infection. IL-6
is the soluble inﬂammatory marker most strongly associated
with mortality in most prior adult studies [9, 10, 13, 15, 16],
and was the only biomarker to be associated with mortality
independently of CD4+ T-cell count in our cohort. CRP was
similarly predictive but did not have an independent additional
effect in our models, consistent with their close biological in-
terdependence, as IL-6 induces hepatic synthesis of this acute-
phase protein [29]. We found no independent effect of TNF-α
or sCD14 on morbidity and mortality. Viral load also had a less
strong association with outcome than IL-6 or CD4+ T-cell
count, and there was no independent effect of age or baseline
disease stage. Whereas immune activation and inﬂammation
are recognized to occur in HIV-infected children [30–42], the
drivers of these processes are poorly characterized [18], and
our analysis highlights the complex network of interrelation-
ships between inﬂammatory markers (Supplementary Figure 3).
The relative contributions of viral replication, coinfections, mi-
crobial translocation, malnutrition, and other factors across
ages and populations may affect the precise inﬂammatory mi-
lieu and clinical outcome of an HIV-infected individual and
may explain both the similarities and the differences between
this study and prior adult studies [9–11, 13–17].
Using hierarchical clustering, we identiﬁed 4 subgroups of
children with different patterns of pre-ART laboratory factors
that were strongly associated with outcome during ART.
Group 1 comprised children with low CD4+ T-cell counts
and high clinical event rates, reﬂecting the well-recognized in-
fection risk among children with profound immunosuppression
[7]. This group also had the largest number of immunological
nonresponders, likely because of failure of homeostatic CD4+
T-cell regenerative mechanisms. Group 2 had similar mortal-
ity to group 1 but comprised younger children with less severe
immunosuppression but high levels of inﬂammation and mal-
nutrition. This highlights the fact that the 2 important pathways
to mortality identiﬁed in our study and others [16, 43, 44]—
immunodeﬁciency and inﬂammation—do not necessarily over-
lap: some children have profound immunosuppression with
modest inﬂammation, whereas others have moderate immuno-
suppression with profound inﬂammation. Most children in our
cohort fell into groups 3 and 4: despite differences in age and
viral load between these groups, pre-ART CD4+ T-cell counts
were similar, and both groups had low event rates, reﬂecting
the excellent clinical outcomes of many children initiating
ART in sub-Saharan Africa [19].
These ﬁndings provide several insights into the pathogenesis
of pediatric HIV infection and indicate potential approaches to
identifying high-risk children and targeting interventions to im-
prove outcomes. Where available, laboratory monitoring cur-
rently relies on CD4+ T-cell count and viral load to identify
children at highest risk of early death. The CD4+ T-cell count
has long been recognized as the best available prognostic mark-
er, and, in this study, children with profound immunosuppres-
sion had high mortality, as expected. However, we also found
that children with very similar pre-ART CD4+ T-cell counts
can have very different clinical outcomes, depending on the pre-
vailing inﬂammatory milieu. A point-of-care test measuring a
soluble inﬂammatory biomarker such as IL-6 or CRP may iden-
tify children who are considered at high risk on the basis of their
inﬂammatory status, rather than their immune status. These
children may beneﬁt from additional interventions at ART ini-
tiation to improve outcomes, although further studies are need-
ed to characterize the drivers of inﬂammation in pediatric
HIV infection, to inform what these interventions might be.
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Children in group 2 had higher rates of intercurrent infections
and antibiotic use at baseline as compared to other groups, and
overt infections may have partly driven pre-ART inﬂammation.
These children also had high a high prevalence of moderate and
severe wasting, and it is recognized that even asymptomatic
malnourished children may have subclinical infections [45],
which may have contributed to inﬂammation; we found a mod-
est inverse association between IL-6 level and weight for age,
providing some support for this premise. Furthermore, these
children were more likely than those in group 1 to develop tu-
berculosis after ART initiation; although we did not have specif-
ic data on immune reconstitution inﬂammatory syndrome, it is
plausible that some had subclinical tuberculosis at baseline that
was unmasked after ART initiation. A pragmatic approach to
reducing mortality may be to provide a package of interventions
at ART initiation that are directed at multiple mechanistic
pathways, including clinical and subclinical infections and
malnutrition. The REALITY trial (ISRCTN43622374), cur-
rently underway in 4 countries in sub-Saharan Africa, is eval-
uating the independent and combined effect of additional
antimicrobial, anti-HIV, and nutritional interventions at
ART initiation on early mortality among adults and children
with profound immunosuppression.
This study has several strengths and limitations. We studied a
large, well-characterized cohort of children initiating ART across
a range of ages and CD4+ T-cell counts in 2 high-burden coun-
tries, with longitudinal biospecimen collection and long-term
outcome data. However, death and WHO clinical stage 4 events
occurred in a relatively small proportion of children in the immu-
nology substudy (the last 6 months of recruitment), who there-
fore formed more of the controls. All analyses adjusted for this
factor, and analyses based on unmatched case-control or strati-
ﬁed case-cohort designs gave similar results, suggesting this
had little inﬂuence, if any. Assessing WHO clinical stage 3 and
4 events can be difﬁcult in children, andmost diagnoses were pre-
sumptive. However, all reportedWHO clinical stage 3 and 4 con-
ditions (and deaths) were reviewed by an independent end-point
review committee against diagnostic criteria prespeciﬁed in the
trial protocol ensuring consistency. Since peripheral blood
mononuclear cells were not available for the vast majority of chil-
dren in this study, we were limited to measuring circulating plas-
ma levels of cytokines and acute-phase proteins, rather than
cellular responses following stimulation. Children were recruited
in 2007–2008, at the start of pediatric ART rollout, and all met
WHO criteria for ART initiation at the time and thus had mod-
erate immunosuppression; further studies from different settings
that include more children treated under universal ART guide-
lines, potentially with less severe immunosuppression, are needed
to conﬁrm our ﬁndings.
In summary, independently of immunosuppression, inﬂam-
mation is a major driver of adverse outcomes during ART in
HIV-infected children initiating ART in sub-Saharan Africa,
similar to ﬁndings for adults [9–11, 13–17, 44]. Children most
at risk of this inﬂammation-associated mortality have moderately
preserved CD4+ T-cell counts and so will not be identiﬁed by cur-
rent routine testing. Our data suggest that targeting HIV-related
inﬂammation is a logical management approach in some high-
risk children, as in adults. While most children initiating ART
in sub-Saharan Africa have excellent long-term outcomes, a sub-
stantial minority die despite ART [3, 6, 8], and there is a critical
need for novel approaches in this group, particularly as more chil-
dren initiate ART under new universal treatment guidelines.
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